Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing
- 1 May 2009
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (13) , 2111-2113
- https://doi.org/10.1200/jco.2008.21.0534
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Cost Effectiveness of Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane TreatmentJournal of Clinical Oncology, 2009
- Saying No Isn't NICE — The Travails of Britain's National Institute for Health and Clinical ExcellenceNew England Journal of Medicine, 2008
- Ixabepilone in Combination with Capecitabine and as Monotherapy for Treatment of Advanced Breast Cancer Refractory to Previous ChemotherapiesClinical Cancer Research, 2008
- Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane TreatmentJournal of Clinical Oncology, 2007
- The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancerCancer, 2007
- Impact of chemotherapy beyond the first line in patients with metastatic breast cancerBreast Cancer Research and Treatment, 2007
- Economic Evaluation in the Journal of Clinical Oncology: Past, Present, and FutureJournal of Clinical Oncology, 2007
- Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)Journal of Clinical Oncology, 2003
- Sequential Single-Agent Chemotherapy for Metastatic Breast Cancer: Therapeutic Nihilism or Realism?Journal of Clinical Oncology, 2003
- The Health Utilities Index (HUI ® ): concepts, measurement properties and applicationsHealth and Quality of Life Outcomes, 2003